BRAF+MEK抑制的免疫效应。
Immunological effects of BRAF+MEK inhibition.
作者信息
Ascierto Paolo A, Dummer Reinhard
机构信息
Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori - IRCCS Fondazione "G. Pascale", Napoli, Italy.
Department of Dermatology, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.
出版信息
Oncoimmunology. 2018 Jul 23;7(9):e1468955. doi: 10.1080/2162402X.2018.1468955. eCollection 2018.
Abstract
Recent developments in immunotherapy have prolonged overall survival in metastatic melanoma with the possibility to reach a long-term benefit. Targeted therapies based on BRAF and MEK inhibition also seem to have a long-term beneficial effect, which is more evident in patients with favorable baseline characteristics, namely normal levels of lactate dehydrogenase, without brain metastases, and low tumor burden. This long-term benefit of targeted therapies might be related to an immune-modulation: indeed BRAF and MEK inhibitors affect tumor microenvironment and immune surveillance, and it has been shown that patients with complete response to targeted treatment have a pre-existing favorable immunologic signature.
摘要
免疫疗法的最新进展延长了转移性黑色素瘤患者的总生存期，并有可能带来长期益处。基于BRAF和MEK抑制的靶向治疗似乎也具有长期有益效果，这在具有良好基线特征的患者中更为明显，即乳酸脱氢酶水平正常、无脑转移且肿瘤负荷低的患者。靶向治疗的这种长期益处可能与免疫调节有关：事实上，BRAF和MEK抑制剂会影响肿瘤微环境和免疫监视，并且已经表明，对靶向治疗完全缓解的患者具有预先存在的良好免疫特征。
相似文献
1
Immunological effects of BRAF+MEK inhibition.BRAF+MEK抑制的免疫效应。
Oncoimmunology. 2018 Jul 23;7(9):e1468955. doi: 10.1080/2162402X.2018.1468955. eCollection 2018.
2
The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.立体定向放射外科联合免疫检查点抑制剂或靶向治疗黑色素瘤脑转移患者：一项回顾性研究。
J Neurooncol. 2020 Jan;146(1):181-193. doi: 10.1007/s11060-019-03363-0. Epub 2019 Dec 14.
3
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.黑色素瘤研究的未来展望：“黑色素瘤桥梁”会议报告：那不勒斯，2014年12月3日至6日
J Transl Med. 2015 Nov 30;13:374. doi: 10.1186/s12967-015-0736-1.
4
Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.免疫治疗时代BRAF靶向治疗的优化应用
Curr Oncol Rep. 2016 Nov;18(11):67. doi: 10.1007/s11912-016-0554-5.
5
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?黑色素瘤中针对BRAF靶向治疗的免疫反应：靶向治疗是免疫治疗吗？
Crit Rev Oncog. 2016;21(1-2):83-91. doi: 10.1615/CritRevOncog.2016017150.
6
Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.BRAF 和 MEK 抑制治疗转移性、不可切除和辅助治疗黑色素瘤的最新进展。
Expert Opin Drug Saf. 2019 May;18(5):381-392. doi: 10.1080/14740338.2019.1607289. Epub 2019 Apr 24.
7
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.免疫治疗和靶向治疗晚期黑色素瘤的系统评价和网络荟萃分析。
Cancer Med. 2017 Jun;6(6):1143-1153. doi: 10.1002/cam4.1001. Epub 2017 May 1.
8
Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma.BRAF-MEK 抑制和免疫检查点抑制在转移性黑色素瘤中的综合临床试验数据总结。
Oncologist. 2019 Nov;24(11):e1197-e1211. doi: 10.1634/theoncologist.2018-0876. Epub 2019 May 7.
9
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.BRAF 和 MEK 抑制剂的免疫调节作用：对黑色素瘤治疗的影响。
Pharmacol Res. 2018 Oct;136:151-159. doi: 10.1016/j.phrs.2018.08.019. Epub 2018 Aug 23.
10
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.BRAF和MEK抑制剂免疫疗法对BRAF（V600E）黑色素瘤的抗肿瘤活性增强
Sci Transl Med. 2015 Mar 18;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691.
引用本文的文献
1
Targeted therapies induced depigmentation: a review.靶向治疗引起的色素脱失：综述
Front Immunol. 2025 Aug 8;16:1625738. doi: 10.3389/fimmu.2025.1625738. eCollection 2025.
2
The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis.达拉非尼联合曲美替尼治疗脑转移黑色素瘤患者的安全性和有效性：一项系统评价和荟萃分析。
Discov Oncol. 2025 Jun 3;16(1):996. doi: 10.1007/s12672-025-02778-8.
3
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.小分子B-RAF抑制剂作为抗癌治疗药物：发现、开发及机制研究进展
Int J Mol Sci. 2025 Mar 16;26(6):2676. doi: 10.3390/ijms26062676.
4
Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status.脑转移的存在根据BRAF突变状态对黑色素瘤一线治疗后的长期生存有不同影响。
Front Immunol. 2025 Feb 14;16:1536642. doi: 10.3389/fimmu.2025.1536642. eCollection 2025.
5
Addition of anti-PD-1 immunotherapy to BRAF inhibitor-based targeted therapy improves real-world survival and delays brain metastases in patients with BRAF-mutant advanced melanoma: a multicenter cohort study.在BRAF抑制剂靶向治疗基础上加用抗PD-1免疫疗法可改善BRAF突变型晚期黑色素瘤患者的实际生存率并延缓脑转移：一项多中心队列研究。
MedComm (2020). 2025 Feb 17;6(3):e70102. doi: 10.1002/mco2.70102. eCollection 2025 Mar.
6
The tumour microenvironment of pilocytic astrocytoma evolves over time via enrichment for microglia.毛细胞型星形细胞瘤的肿瘤微环境通过小胶质细胞的富集随时间演变。
Acta Neuropathol Commun. 2025 Feb 13;13(1):30. doi: 10.1186/s40478-024-01922-9.
7
Safety and Efficacy Analysis of Targeted and Immune Combination Therapy in Advanced Melanoma-A Systematic Review and Network Meta-Analysis.晚期黑色素瘤靶向与免疫联合治疗的安全性和疗效分析——一项系统评价与网状Meta分析
Int J Mol Sci. 2024 Nov 28;25(23):12821. doi: 10.3390/ijms252312821.
8
Innate Immune Cells in Melanoma: Implications for Immunotherapy.固有免疫细胞在黑色素瘤中的作用：免疫治疗的启示。
Int J Mol Sci. 2024 Aug 5;25(15):8523. doi: 10.3390/ijms25158523.
9
Activation of the MAPK network provides a survival advantage during the course of COVID-19-induced sepsis: a real-world evidence analysis of a multicenter COVID-19 Sepsis Cohort.丝裂原活化蛋白激酶（MAPK）网络的激活在新型冠状病毒肺炎（COVID-19）诱发的脓毒症病程中提供了生存优势：一项多中心COVID-19脓毒症队列的真实世界证据分析
Infection. 2025 Feb;53(1):107-115. doi: 10.1007/s15010-024-02325-7. Epub 2024 Jun 19.
10
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma.基质浸润 T 细胞表型定义了青少年和年轻成年黑色素瘤患者免疫治疗的效果。
Nat Commun. 2024 Apr 8;15(1):3014. doi: 10.1038/s41467-024-47301-9.
本文引用的文献
1
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.恩考芬尼加比美替尼与维莫非尼或恩考芬尼用于治疗 BRAF 突变型黑色素瘤患者（COLUMBUS）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21.
2
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.新辅助加辅助达拉非尼和曲美替尼与高危可切除黑色素瘤患者的标准治疗相比：一项单中心、开放标签、随机、2 期临床试验。
Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.
3
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.联合使用 AXL 抗体药物偶联物和 BRAF/MEK 抑制剂靶向黑色素瘤异质性。
Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15.
4
Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.达拉非尼联合曲美替尼治疗 BRAF V600 突变型转移性黑色素瘤患者的长期结局。
J Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9.
5
MEK inhibition and immune responses in advanced melanoma.晚期黑色素瘤中的MEK抑制与免疫反应
Oncoimmunology. 2017 Aug 10;6(8):e1335843. doi: 10.1080/2162402X.2017.1335843. eCollection 2017.
6
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.辅助达拉非尼联合曲美替尼治疗 BRAF 突变型 III 期黑色素瘤。
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
7
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.纳武利尤单抗联合伊匹木单抗治疗晚期黑色素瘤的总生存期
N Engl J Med. 2017 Oct 5;377(14):1345-1356. doi: 10.1056/NEJMoa1709684. Epub 2017 Sep 11.
8
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.因不良事件而停用纳武利尤单抗和伊匹木单抗治疗的晚期黑色素瘤患者的疗效和安全性结果：随机II期和III期试验的汇总分析
J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.
9
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?黑色素瘤中的检查点抑制剂和实体肿瘤的早期开发：未来如何？
J Transl Med. 2017 Aug 8;15(1):173. doi: 10.1186/s12967-017-1278-5.
10
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.晚期转移性黑色素瘤患者的生存情况：新型疗法的影响——2017年更新
Eur J Cancer. 2017 Sep;83:247-257. doi: 10.1016/j.ejca.2017.06.028. Epub 2017 Aug 23.
Zotero 插件